Accumulating evidence indicates tumor necrosis factor-alpha (TNF-alpha) as a key cytokine in the pathogenesis of the myelodysplastic syndromes (MDS). The identification of TNF-alpha as a regulator of apoptosis and the increased susceptibility of MDS cells to this cytokine provided the basis for several clinical trials of TNF inhibitors. Infliximab is an IgG(1) chimeric anti-TNF-alpha monoclonal antibody composed of human constant and murine variable regions that bind specifically to both soluble and membrane-bound TNF-alpha. To date, only 2 studies have investigated the use of infliximab in patients with low-risk MDS. In both reports the drug showed a limited but significant activity and a favorable side-effect profile. In some patients, hematopoietic response was associated with decreased apoptosis as well as a decrease in abnormal metaphases by 50%. Further studies are currently underway and should provide useful information to de. ne the more responsive subtypes of MDS, the patient characteristics, and the proper dosing regimen.

Stasi R., A.S. (2005). Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes. LEUKEMIA & LYMPHOMA, 46(4), 509-516 [10.1080/10428190400027829].

Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes

AMADORI, SERGIO;
2005

Abstract

Accumulating evidence indicates tumor necrosis factor-alpha (TNF-alpha) as a key cytokine in the pathogenesis of the myelodysplastic syndromes (MDS). The identification of TNF-alpha as a regulator of apoptosis and the increased susceptibility of MDS cells to this cytokine provided the basis for several clinical trials of TNF inhibitors. Infliximab is an IgG(1) chimeric anti-TNF-alpha monoclonal antibody composed of human constant and murine variable regions that bind specifically to both soluble and membrane-bound TNF-alpha. To date, only 2 studies have investigated the use of infliximab in patients with low-risk MDS. In both reports the drug showed a limited but significant activity and a favorable side-effect profile. In some patients, hematopoietic response was associated with decreased apoptosis as well as a decrease in abnormal metaphases by 50%. Further studies are currently underway and should provide useful information to de. ne the more responsive subtypes of MDS, the patient characteristics, and the proper dosing regimen.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - Malattie del Sangue
English
infliximab; myelodysplastic syndromes; tumor necrosis factor-alpha; apoptosis
Stasi R., A.S. (2005). Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes. LEUKEMIA & LYMPHOMA, 46(4), 509-516 [10.1080/10428190400027829].
Stasi, R; Amadori, S; Newland, Ac; Provan, D
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/41642
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 19
social impact